Study of a new drug for acute schizophrenia symptoms
Treatments studied
Part of Mental health clinical trials.
This trial tests an investigational medication called VV119 for adults experiencing a sudden worsening of schizophrenia symptoms. It aims to see if the drug is safe and effective in reducing symptoms like delusions, hallucinations, and disorganized thinking.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have a diagnosis of schizophrenia and are currently having a flare-up of symptoms that started less than 2 months ago.
- Your symptoms are severe enough that you might need to be in the hospital, or you have been hospitalized for this flare-up for 2 weeks or less.
- You are not currently taking certain other psychiatric medications, or you can stop them for a short time before starting the study.
- You agree to use effective birth control during the study and for 3 months after the last dose.
- You have not had a poor response to aripiprazole (a common antipsychotic) in the past.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a new drug called VV119 is safe and how it works in the body. It is for healthy volunteers and for people who have had schizophrenia for at least a year and are currently having worsening symptoms.
This study tests a new medication (LY03020) for people with schizophrenia who are currently having a flare-up of symptoms severe enough to require hospital care. The goal is to see if the drug safely reduces psychotic symptoms like hallucinations and delusions.
This trial tests a new drug, GXV813, to see if it helps reduce symptoms in people with schizophrenia who are currently hospitalized due to a sudden worsening of their condition. It compares the drug's safety and effect against a placebo over several weeks.
This trial tests an investigational medicine called NBI-1117568 in adults with schizophrenia who are currently having a relapse or worsening of symptoms and need to stay in the hospital. The goal is to see if the medicine is safe and effective.
This study tests an experimental drug (NBI-1117568) for people with schizophrenia who are currently in the hospital due to worsening symptoms. Participants stop their current antipsychotic and take the study drug to see if it can help control symptoms.
This study tests whether a new long-acting injection of aripiprazole (a medication for schizophrenia) works the same as the current version. It helps understand how the drug is absorbed and may offer a more convenient treatment option for people with stable schizophrenia.
Hear when a new Schizophrenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.